Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Targovax ASA ( (GB:0RIS) ).
Circio reported strong technical progress in the second half of 2025, including up to 40-fold enhanced AAV-mediated gene expression in heart tissue and up to 50-fold in the eye using advanced generations of its circVec platform. The company also secured a fully funded feasibility study with a top five global pharmaceutical partner, signaling rising industry interest in its circular RNA gene therapy technology.
The biotech further expanded its scientific footprint through new research collaborations with The University of Texas Medical Branch in infectious diseases and United Immunity on in vivo CAR-macrophage therapy. Financially, Circio completed an oversubscribed rights issue in the first quarter of 2026, raising about NOK 68.6 million and ending March with NOK 42 million in cash, while gaining added visibility with an abstract accepted for oral presentation at the ASGCT meeting in Boston in May 2026.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing novel circular RNA expression technology for gene and cell therapies. Its proprietary circVec platform uses modular genetic constructs to produce multifunctional circular RNA in target cells, aiming to significantly extend RNA half-life and boost protein expression over conventional mRNA-based viral and non-viral vectors.
Average Trading Volume: 10,110,733
Current Market Cap: NOK2.09B
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.